TrialEBioMedicine2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Meera Madhavan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
100 papers cite itlatest 60 shown
this paperpooled ittrialcites it